Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $81.10.

Several research firms have recently commented on HSIC. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, February 26th. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Barrington Research reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Jefferies Financial Group lifted their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd.

Henry Schein Trading Up 2.1 %

Shares of HSIC opened at $72.96 on Friday. The stock has a market capitalization of $9.06 billion, a P/E ratio of 30.02, a PEG ratio of 2.13 and a beta of 0.91. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $74.44 and a two-hundred day simple moving average of $72.51. Henry Schein has a twelve month low of $63.67 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period in the prior year, the business posted $0.66 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts anticipate that Henry Schein will post 4.74 EPS for the current year.

Institutional Trading of Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Clarkston Capital Partners LLC grew its stake in shares of Henry Schein by 5.4% in the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock worth $101,900,000 after acquiring an additional 71,560 shares during the period. Nuance Investments LLC grew its stake in shares of Henry Schein by 22.3% in the third quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock worth $166,072,000 after acquiring an additional 414,748 shares during the period. Olstein Capital Management L.P. boosted its holdings in shares of Henry Schein by 17.2% in the fourth quarter. Olstein Capital Management L.P. now owns 109,000 shares of the company’s stock worth $7,543,000 after buying an additional 16,000 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Henry Schein in the third quarter worth approximately $515,000. Finally, Private Management Group Inc. boosted its holdings in shares of Henry Schein by 5.7% in the fourth quarter. Private Management Group Inc. now owns 350,515 shares of the company’s stock worth $24,256,000 after buying an additional 18,882 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.